Find Paper, Faster
Example:10.1021/acsami.1c06204 or Chem. Rev., 2007, 107, 2411-2502
Health Status and Cardiac Rehabilitation—Putting a Dollar Amount on Improvement
JAMA Cardiology  (IF14.676),  Pub Date : 2021-11-24, DOI: 10.1001/jamacardio.2021.4844
Paul A. Heidenreich

As the number and price of novel medical treatments accelerate, there is heightened interest in determining their value. A price typically reflects a manufacturer’s estimate of society’s willingness to pay for their product. Treatments that improve survival appropriately command higher prices, although the correlation is not close, as noted by recent prices of proprotein convertase subtilisin/kexin type 9 inhibitors, sodium-glucose contransporter 2 inhibitors, combined sacubitril-valsartan, and transthyretin tetramer stabilizer therapy. Most of us accept that society should pay extra for a treatment that improves survival, but what about therapies that have as their main effect an improvement in health status?